The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...

With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.

Learn more› By Erin Roberts and Ben Keough After considering new apps, we still think that Adobe Lightroom and Snapseed are the best choices for editing photos when you’re away from a desktop ...

New gene therapies could transform sickle cell treatment forever. A future without pain crises or hospitalizations may finally be within reach.

January 31, 2025 expert reaction to NICE final draft guidance on exagamglogene autotemcel (exa-cel) for severe sickle cell disease . Scientists comment on final draft guidance fro ...

The PIF/Harbinger-derived ADF-IL protein recruits KAT2B to drive its nuclear translocation and local chromatin acetylation, ...

Learn more about whether Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ ...

BEAM’s pipeline of gene editing therapies is based on its proprietary ... with BEAM-101 led to a robust and durable increase in fetal hemoglobin of more than 60% and a reduction in sickle ...

In this installment of Rebelliously Curious, we delve into one of the most debated scientific advancements of our time: CRISPR gene-editing technology. Joining us is Neal Baer, M.D.—pediatrician, ...

Detailed price information for Beam Therapeutics Inc (BEAM-Q) from The Globe and Mail including charting and trades.

Key criticisms of the article include the current inaccuracy of gene-editing technologies, the challenges in accurately identifying causal gene variants, and the possibility of pleiotropic effects ...